EGFR and cancer: The fact that Stat3 is only activated by low-affinity receptors in every cell type that we examined suggests that in vivo concentrations of EGFR ligands can stimulate low-affinity receptors and identifies a possible role for low-affinity receptors in the in vivo signaling of cancer cells.